ETERNA THERAPEUTICS INC (ERNA)
US1140822099 - Common Stock
Curious about the stocks that are showing activity after the closing bell on Monday?
Curious about the stocks that are showing activity after the closing bell on Monday?
Top movers in Friday's after hours session
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Eterna Therapeutics Announces $1 Million Stock Repurchase Program...
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing ...
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success...
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited...
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024
Eterna Therapeutics just reported results for the second quarter of 2024.
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eterna Therapeutics (NASDAQ:ERNA) just reported results for the second quarter ...
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024
Eterna Therapeutics just reported results for the first quarter of 2024.
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eterna Therapeutics (NASDAQ:ERNA) just reported results for the first quarter o...
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs
Eterna Therapeutics to Present at ASGCT on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line...
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board...
ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost
Intuitive Surgical stock is on the rise Friday as investors in ISRG shares learn about FDA approval for the company's da Vinci 5.
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023
Eterna Therapeutics just reported results for the fourth quarter of 2023.
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
Eterna Therapeutics (ERNA) Announces the Appointment of Peter Cicala, JD, to its Board of Directors...
Eterna Therapeutics files to sell 18.2M shares for holders (NASDAQ:ERNA)
Eterna Therapeutics files prospectus for $25M mixed shelf offering, not an offer to sell securities.
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics names Sanjeev Luther as CEO (NASDAQ:ERNA)
Eterna Therapeutics names Sanjeev Luther as President and CEO.
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics launches convertible debt and warrant financing of up to $9.2M (ERNA)
Eterna Therapeutics secures $9.2 million through the sale of convertible promissory notes and warrants in a private placement.
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start of the trading week with a look at the biggest pre-market stock movers worth watching on Monday morning!
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed...
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
mRNA cell engineering strategically targets genes to create novel and potentially superior product profiles for cell transplant therapy applications Novel...